Renin-Angiotensin-Aldosterone System Inhibitor Use and Mortality in Pulmonary Hypertension: Insights From the Veterans Affairs Clinical Assessment Reporting and Tracking Database.

ABSTRACT:

Background

The renin-angiotensin-aldosterone system (RAAS) contributes to pulmonary hypertension (PH) pathogenesis. Although animal data suggest that RAAS inhibition attenuates PH, it is unknown if RAAS inhibition is beneficial in PH patients.

Research question

Is RAAS inhibitor use associated with lower mortality in a large cohort of patients with hemodynamically confirmed PH?

Study design and methods

We used the Department of Veterans Affairs Clinical Assessment Reporting and Tracking Database to study retrospectively relationships between RAAS inhibitors (angiotensin converting enzyme inhibitors [ACEIs], angiotensin receptor blockers [ARBs], and aldosterone antagonists [AAs]) and mortality in 24,221 patients with hemodynamically confirmed PH. We evaluated relations

SUBMITTER: Lahm T 

PROVIDER: S-EPMC8173779 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature